Nadipelli VR, Solem CT, Ronquest NA, Yeh Y, Heidbreder C, Learned SM, Mehra V. Impact of RBP-6000 on patient-reported outcomes in patients with opioid use disorder: results of a randomized, placebo-controlled, phase 3 study. Poster presented at the 41st Association of Medical Education and Research in Substance Abuse (AMERSA) Annual National Conference; November 2017. Washington, DC. doi: 10.1080/08897077.2018.1441944
Ramamohan V, Mladsi D, Ronquest N, Kamat S, Boklage S. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia. Hospital Practice. 2017 Aug;45(3):111-7. doi: 10.1080/21548331.2017.1324227
Wollschlaeger BA, Willson TM, Montejano LB, Ronquest NA, Nadipelli VR. Characteristics and treatment patterns of US commercially insured and Medicaid patients with opioid dependence or abuse. J Opioid Manag. 2017 Jul;13(4):207-20. doi: 10.5055/jom.2017.0389
Ruetsch C, Tkacz J, Nadipelli VR, Brady BL, Ronquest N, Un H, Volpicelli J. Heterogeneity of nonadherent buprenorphine patients: subgroup characteristics and outcomes. Am J Manag Care. 2017 Jun 1;23(6):e172-9.
Sabar U, Rycroft C, Ronquest NA, Nadipelli VR, Wollschlaeger B, Akehurst R. Analysis of humanistic burden reveals a need for opioid use disorder (OUD) disease-specific HRQoL instruments. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A300.
Sabar U, Rycroft C, Ronquest NA, Nadipelli VR, Wollschlaeger B, Akehurst R. The economic burden of opioid use disorder (OUD): results of a structured literature review. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A298.